S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Co-Diagnostics Stock Forecast, Price & News

+0.23 (+4.10%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
38,378 shs
Average Volume
439,458 shs
Market Capitalization
$198.49 million
P/E Ratio
Dividend Yield
Price Target

Co-Diagnostics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
122.6% Upside
$13.00 Price Target
Short Interest
5.44% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.60mentions of Co-Diagnostics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.67 to $0.71 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.16 out of 5 stars

Medical Sector

315th out of 1,427 stocks

Surgical & Medical Instruments Industry

38th out of 138 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Co-Diagnostics logo

About Co-Diagnostics (NASDAQ:CODX) Stock

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CODX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$36.66 million
Pretax Margin


Sales & Book Value

Annual Sales
$97.89 million
Cash Flow
$1.28 per share
Book Value
$4.65 per share


Free Float
Market Cap
$198.49 million
Not Optionable

Co-Diagnostics Frequently Asked Questions

Should I buy or sell Co-Diagnostics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics
or view top-rated stocks.

What is Co-Diagnostics' stock price forecast for 2022?

4 equities research analysts have issued 1 year price targets for Co-Diagnostics' shares. Their CODX stock forecasts range from $12.00 to $14.00. On average, they anticipate Co-Diagnostics' stock price to reach $13.00 in the next year. This suggests a possible upside of 122.6% from the stock's current price.
View analysts' price targets for Co-Diagnostics
or view top-rated stocks among Wall Street analysts.

How has Co-Diagnostics' stock performed in 2022?

Co-Diagnostics' stock was trading at $8.93 on January 1st, 2022. Since then, CODX shares have decreased by 34.6% and is now trading at $5.84.
View the best growth stocks for 2022 here

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Co-Diagnostics

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) issued its earnings results on Thursday, May, 12th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.18 by $0.08. The firm earned $22.70 million during the quarter, compared to analysts' expectations of $21.25 million. Co-Diagnostics had a net margin of 40.25% and a trailing twelve-month return on equity of 32.20%. During the same quarter in the previous year, the business earned $0.26 earnings per share.
View Co-Diagnostics' earnings history

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics updated its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided EPS guidance of $0.170-$0.200 for the period, compared to the consensus estimate of $0.110. The company issued revenue guidance of $21 million-$22 million, compared to the consensus revenue estimate of $21.28 million.

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 69, Pay $1.02M)
  • Mr. Brian L. Brown CPA, CFO & Company Sec. (Age 46, Pay $730.62k)
  • Mr. Reed L. Benson, Gen. Counsel (Age 74, Pay $385.85k) (LinkedIn Profile)
  • Dr. Brent C. Satterfield Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 45)
  • Dr. Jesse Montgomery, Chief Scientific Officer
  • Mr. Andrew Benson, Head of Investor Relations
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $5.84.

How much money does Co-Diagnostics make?

Co-Diagnostics (NASDAQ:CODX) has a market capitalization of $198.49 million and generates $97.89 million in revenue each year. The company earns $36.66 million in net income (profit) each year or $1.30 on an earnings per share basis.

How many employees does Co-Diagnostics have?

Co-Diagnostics employs 101 workers across the globe.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The official website for Co-Diagnostics is www.codiagnostics.com. The company can be reached via phone at (801) 438-1036 or via email at investors@codiagnostics.com.

This page (NASDAQ:CODX) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.